コンテンツへスキップ
Merck
すべての画像(1)

資料

安全性情報

B-006

Supelco

ブタルビタール 溶液

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

別名:

5-アリル-5-イソブチルバルビツル酸

ログイン組織・契約価格を表示する
すべての画像(1)

About This Item

実験式（ヒル表記法）:
C11H16N2O3
CAS番号:
77-26-9
分子量:
224.26
MDL番号:
MFCD00056089
UNSPSCコード:
41116107
PubChem Substance ID:
329773093
NACRES:
NA.24

グレード

certified reference material

形状

liquid

特徴

SNAP-N-SPIKE®, SNAP-N-SHOOT®

包装

ampule of 1 mL

メーカー／製品名

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIC (Portugal)

濃度

1.0 mg/mL in methanol

テクニック

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

アプリケーション

forensics and toxicology

フォーマット

single component solution

保管温度

2-8°C

SMILES記法

CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O

InChI

1S/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)

InChI Key

UZVHFVZFNXBMQJ-UHFFFAOYSA-N

遺伝子情報

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

類似した製品をお探しですか？ 訪問 製品比較ガイド

関連するカテゴリー

詳細

Butalbital is a barbiturate often combined with other medications such as acetaminophen or aspirin for the treatment of pain or codeine for headaches. Trade names of several butalbital combinations include Axocet®, Bucet, and Bupap® with acetaminophen and Axotal with aspirin. This certified reference solution is suitable for GC/MS or LC/MS applications in forensic analysis, clinical toxicology or urine drug testing.

アプリケーション


  • Butalbital API for Research: Investigates Butalbital as an active pharmaceutical ingredient (API), focusing on its properties and applications in synthesizing complex pharmaceutical formulations, essential for developing new barbiturate-based treatments (Yang et al., 2022).

  • Butalbital Compound Synthesis: Explores the synthesis of Butalbital and its derivatives, underlining its critical role in the development of CNS depressants and its pharmacological potential in neurobiological research (Marmura et al., 2015).

  • Barbiturate Biochemical Research: Focuses on Butalbital′s effects on human platelet aggregation, offering insights into its mechanism of action within the cardiovascular system, which is vital for tailoring barbiturate-based therapies (Sato et al., 2003).

  • Butalbital Pharmacological Studies: Discusses the pharmacological profiling of Butalbital, emphasizing its utility in managing acute pain and headaches, thereby supporting its continued use in clinical settings for migraine and tension headache relief (Mazer-Amirshahi et al., 2014).

  • CNS Depressant Research Chemical: Analyzes Butalbital′s role as a central nervous system depressant, assessing its effectiveness and safety profile, which is crucial for its application in chronic pain management and treatment of cluster headaches (Cutrer et al., 1999).



法的情報

Axocet is a registered trademark of Fougera Pharmaceuticals Inc.
Bupap is a registered trademark of ECR Pharmaceuticals Co., Inc.
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

ピクトグラム

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

シグナルワード

Danger

危険有害性情報

H225,H301 + H311 + H331,H370

危険有害性の分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

保管分類コード

3 - Flammable liquids

WGK

WGK 1

引火点(°F)

49.5 °F - closed cup

引火点(℃)

9.7 °C - closed cup

適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

消防法

第4類:引火性液体
アルコール類
危険等級II

Jan Code

B-006-1ML:4548173317526
B-006-CC:

試験成績書（COA）

製品のロット番号・バッチ番号を入力して、試験成績書（COA） を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

Seymour Solomon
Current pain and headache reports, 6(2), 147-150 (2002-03-02)
Butalbital compounds are of proven efficacy in the treatment of tension headache. Decades of experience have established their value in the treatment of other mild-to-moderate headaches. Untold numbers of people rely on these medications as their drug of choice or
William B Young et al.
Current pain and headache reports, 6(2), 151-155 (2002-03-02)
In the United States analgesic-overuse headache is often caused by butalbital-containing analgesics. These agents can cause physical and psychological dependency, and dangerous withdrawal syndromes. Butalbital-containing analgesics have already been banned in several European countries. They are proven effective in tension-type
W T Chang et al.
Journal of analytical toxicology, 25(8), 659-669 (2002-01-05)
As a part of our study on the use of isotopic analogues as the internal standard (IS) for the quantitation of drug analytes, this article reports on the performance characteristics of 2H5-butalbital and 13C4-butalbital with particular focus on (1) determining
Karla A Moore et al.
Forensic science international, 134(2-3), 120-122 (2003-07-10)
Zaleplon ("Sonata") is a pyrazolopyrimidine derivative approved for use in the United States for the treatment of insomnia. To date, there has been little data in the toxicological literature where zaleplon has been implicated as causing a fatal intoxication, either
Richard G Wenzel et al.
Pharmacotherapy, 22(8), 1029-1035 (2002-08-14)
To evaluate the role of butalbital-containing products in the management of migraine. Qualitative systematic search using MEDLINE (January 1966-November 2001), review of the United States Headache Consortium's evidence-based guidelines for migraine treatment, and review of other pertinent literature. Over 28
関連する文献をすべて表示

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら（テクニカルサービス）